Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13.
This study provides valuable experimental evidence for clinical MM therapy. PMID: 31538911 [PubMed - as supplied by publisher]
We reported on a 54-year-old patient with a diagnosis of grade 2 follicular lymphoma (FL) and concomitant renal cancer. After the nephrectomy, the patient underwent two lines of chemoimmunotherapy, autologous stem cell transplant, obtained a complete response with idelalisib and underwent an allogeneic transplant (alloSCT).
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Lauren Finlay, Alison Waldbauer, Christine Chen
In conclusion, our findings link the calcification of the vascular tissue with the expression of FGF23 in the vessels and with the elevation of circulating levels this hormone. Permanently Boosting Levels of Natural Killer Cells in Mice to Increase Cancer Resistance https://www.fightaging.org/archives/2019/09/permanently-boosting-levels-of-natural-killer-cells-in-mice-to-increase-cancer-resistance/ Researchers here demonstrate a very interesting approach to immunotherapy: they introduce engineered stem cells in mice that will give rise to additional natural killer T cells, boosting the capability of the ...
L-type amino acid transporter 1 (LAT1) plays a key role in cell growth and survival. Overexpression is a common feature of many malignancies to support increased protein synthesis demand. Among patients with multiple myeloma, high LAT1 expression has been shown to be associated higher risk disease but also a higher response rate following treatment with oral melphalan in clinical and pre-clinical models (Isoda, et al, Cancer Sci, 2014; Hathi, et al, J Nucl Med, 2018). Oral melphalan is infrequently used in today's clinical practice; however, high-dose intravenous melphalan is the standard of care for conditioning prior to ...
Patients with Multiple Myeloma (MM) are enjoying significant improvement in overall survival as the result of advent of novel anti-myeloma agent that replace traditional chemotherapy, in addition to the increased use of transplant. The prices of novel agents, especially oral ones, have been rapidly escalating and there are well-described issues with affordability (Shih et al. JCO 2017). We therefore hypothesized that insurance status influences MM patients (pts) survival. National Cancer Database (NCDB), covering 70% of MM patient nationwide was utilized.
Historically at Princess Margaret Cancer Centre, cyclophosphamide and GCSF was the standard stem cell mobilization regimen used for transplant eligible multiple myeloma patients. Limitations to this regimen included chemotherapy associated toxicity such as febrile neutropenia, and unpredictability regarding the ideal planned apheresis start date. With the recent validation of open-vial sterility of plerixafor allowing for broader access at our centre (Seki et al. Can J Hosp Pharm 2017;70:270), an opportunity was identified to transition to a less toxic GCSF alone mobilization regimen.
Despite the development of sensitive methods to monitor the residual malignant plasma cell component in Multiple Myeloma (MM) patients, the current assays are limited in that they do not necessarily assess the complete malignant cellular component of the disease, cannot be applied to all MM patients and require painful BM assessments on a regular basis. There is therefore potential room for a completely different approach, investigating the monitoring of the proposed malignant stem cell feeder population circulating in the PB.
In some patients with multiple myeloma (MM), the original M protein disappears and one or multiple smaller immunoglobulins, called oligoclonal bands (OCB), emerge following autologous stem cell transplant (ASCT). OCB are associated with improved disease-free survival (DFS) and may be associated with early immune system recovery. Patients in phase I/II clinical trials at the University of Maryland Greenebaum Cancer Center who received anti CD3-CD28 co-stimulated and engineered autologous T cells shortly after ASCT had early, rapid, and robust T cell recovery.
Treatment of multiple myeloma (MM) with induction chemotherapy followed by autologous hematopoietic cell transplant (auto HCT) improves event-free survival and overall survival. This prolonged survival has unmasked long-term complications related to therapy that impact quality of life. Studies in other cancers have identified cognitive impairment related to chemotherapy treatment based on exposure or dose. To date, there are no studies evaluating the impact auto HCT may have on cognition in MM patients.
PNK-007 is an allogeneic, off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from placental CD34+ cells. PNK-007 exhibit cytotoxicity against various cancer cell types, including multiple myeloma (MM), and secrete cytokines during co-culture with cancer cells. This is a Phase I study of single infusion PNK-007 after autologous stem cell transplant (ASCT) in MM.